Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group

Author:

Hogervorst Milou AmberORCID,Vreman RickORCID,Heikkinen InkatuuliORCID,Bagchi Indranil,Gutierrez-Ibarluzea InakiORCID,Ryll Bettina,Eichler Hans-GeorgORCID,Petelos ElenaORCID,Tunis Sean,Sapede Claudine,Goettsch WimORCID,Janssens Rosanne,Huys Isabelle,Barbier Liese,DeJean Deirdre,Strammiello Valentina,Lingri Dimitra,Goodall Melinda,Papadaki Magdalini,Toussi Massoud,Voulgaraki Despina,Mitan Ania,Oortwijn WijaORCID

Abstract

Abstract Objectives Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface. Methods Six online discussions among WG members (Dec 2021–Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions. Results The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: “unavailable,” “inaccurate,” “conflicting,” “not understandable,” “random variation,” “information,” “prediction,” “impact,” “risk,” “relevance,” “context,” and “judgment.” These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed. Conclusions The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.

Publisher

Cambridge University Press (CUP)

Subject

Health Policy

Reference43 articles.

1. 36. Agrawal, S , Arora, S , Amiri-Kordestani, L , et al. Use of single-arm trials for US Food and Drug Administration Drug approval in oncology, 2002–2021. JAMA Oncol [Internet]. 2022;9:266-272 [cited 2023 Jan 5]; Available from https://doi.org/10.1001/jamaoncol.2022.5985.

2. 37. Bloem, LT , Bot, RE , Mantel‐Teeuwisse, A , et al. Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs; 2021; Available from: https://www.semanticscholar.org/paper/073a48b0c721d44fc7b0bfbd064689ec1a495bd5.

3. Varieties of uncertainty in health care: A conceptual taxonomy;Han;Med Decis Mak Int J Soc Med Decis Mak.,2011

4. Aleatoric and epistemic uncertainty in groundwater flow and transport simulation;Ross;Water Resour Res [Internet],2009

5. 29. Introduction to Health Technology Evaluation | NICE Health Technology Evaluations: The Manual | Guidance | NICE [Internet]. NICE; [cited 2022 Aug 3]. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3